Company alerts

June 2, 2023
Stealth BioTherapeutics
LT -
Longevity pillar
  • -
Longevity domain:
  • -
Longevity target: -
and Pharmanovia partner for commercialisation of elamipretide.
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. Pharmanovia will hold exclusive rights for the commercialisation of elamipretide in the EU, other European countries including Switzerland, Norway, Iceland and the UK, and the Middle East and northern Africa region. The agreement allows Stealth to receive upfront and future payments linked to the achievement of regulatory, development and commercial milestones, and royalties on net sales of elamipretide in the licensed territories.